Validation of a 26-color Spectral Flow Cytometric Assay Aligned with CLSI H62
As immunotherapies, cell therapies, and next-generation vaccines continue to advance, the need for robust, reproducible, and standardized immune monitoring assays has never been greater.
In this poster presented at CYTO 2026, Eurofins Clinical Trial Solutions highlights the development and validation of a 26-color spectral flow cytometry assay aligned with CLSI H62 recommendations. Designed to support comprehensive immune profiling, the assay demonstrates strong precision, reproducibility, stability, and detection capabilities across a broad range of immune cell populations.
Key highlights include:
- Alignment with CLSI H62 guidance for spectral flow cytometry assay validation
- Evaluation of assay precision and reproducibility using a factorial study design
- Assessment of detection capabilities for rare and low-frequency immune cell populations
- Stability testing of whole blood and fixed samples under clinically relevant conditions
- A standardized approach to high-dimensional immunophenotyping for clinical research applications
Access the poster to learn how this validated assay supports reliable, reproducible immune monitoring and enables advanced characterization of immune cell populations in clinical trials.